Suzhou Kintor Pharmaceuticals Inc. has identified protein degradation inducers reported to be useful for the treatment of cancer, viral infection, cardiovascular and cerebrovascular disorders.

Nerviano Medical Sciences Srl has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer, diabetic nephropathy, organ transplant rejection, arthritis, fibrosis, inflammation, neurodegeneration and metabolic diseases.

Researchers at the Japanese Foundation for Cancer Research and RIKEN have disclosed tankyrase 1 (TNKS1; PARP5A) and/or TNKS2 (PARP5B) inhibitors reported to be useful for the treatment of cancer, metabolic disease, cartilage injury, multiple sclerosis, pulmonary fibrosis, amyotrophic lateral sclerosis, herpes simplex virus and Epstein Barr virus infections.

Kymera Therapeutics Inc. has described proteolysis targeting chimeras (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety covalently linked to a cyclin-dependent kinase 2 (CDK2)-targeting moiety through a linker.

Fochon Biosciences Ltd. has divulged apoptosis regulator Bcl-2 (D103E mutant and D103Y mutant) inhibitors reported to be useful for the treatment of autoimmune disease and cancer.

Hotspot Therapeutics Inc. has identified mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer.

Mironid Ltd. has synthesized phosphodiesterase PDE4 activators reported to be useful for the treatment cancer, hyperparathyroidism, autosomal dominant polycystic kidney disease and autosomal recessive polycystic kidney disease.

Astrazeneca AB has disclosed myeloperoxidase inhibitors reported to be useful for the treatment of cancer, cardiovascular, inflammatory, renal, neurological and respiratory disorders and liver diseases.

Insilico Medicine Inc. has patented new cyclin-dependent kinase 12 (CDK12)/cyclin K and/or CDK13 inhibitors reported to be useful for the treatment of cancer, particularly triple-negative breast cancer.

Work at Bellbrook Labs LLC has led to the identification of cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of autoimmune diseases.